Loading...
Cart
0

Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases Expected to Reach $8,579.9 Million by 2025

 
 

quote Increase in demand for noninvasive neurological biomarkers is expected to supplement the market growth. Furthermore, rise in number of research activities focused towards developing efficient biomarkers that can aid in early diagnosis of Alzheimer’s and Parkinson’s diseases is expected to drive the market growth in the near future. For instance, MSDx, Inc. is developing cost-effective and reliable blood-based neurological biomarkers that can aid in detecting the onset of disease before excessive damage occurs. The company has patented the blood test and has named it as the “Window into The Brain. quote

Garima Chandra
Senior Research Analyst, Healthcare at AMR.

Get 20% Free Customization In This Report
Follow us on Social Media:       
 

According to a new report published by Allied Market Research, titled, Customized Study on Neurological Biomarkers Market for Alzheimers and Parkinsons Disease: Global Opportunity Analysis and Industry Forecast, 2017-2025, the global market was valued at $3,958.5 million in 2017, and is projected to reach $8,579.9 million by 2025, growing at a CAGR of 10.1% from 2018 to 2025. China accounted for one-ninth share of the total market of neurological biomarkers for Alzheimers in 2017.

The neurological biomarkers market for Alzheimers disease generated a revenue of $2,636.7 million in 2017, and is expected to reach $6,122.5 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. Conversely, neurological biomarkers market for Parkinsons disease generated a revenue of $1,321.8 million in 2017, and is expected to reach $2,457.4 million by 2025 registering a CAGR of 8.0%.

Upsurge in the incidence of Alzheimers and Parkinsons diseases is anticipated to contribute to the robust growth of neurological biomarkers. In addition, increase in adoption of neurological biomarkers in drug development and validation has been witnessed over the years to improve the accuracy of clinical trials. Furthermore, rise in preference towards personalized medicine is expected to offer profitable opportunities for the expansion of neurological biomarkers applied across Alzheimers and Parkinsons.

Based on the region, the neurological biomarkers market for Alzheimers and Parkinsons diseases is studied across the U.S., EU5, rest of Europe, China, Asia-Pacific, and rest of the world (ROW). The U.S. dominated the market for Alzheimers and Parkinsons in 2017, and is expected to continue this trend throughout the forecast period. In addition, Asia-Pacific is anticipated to grow at the fastest pace in Alzheimers neurological biomarkers market during the forecast period, whereas China is expected to register highest growth rate from 2018 to 2025 in the Parkinsons neurological biomarkers market.

Key Findings of the Neurological Biomarkers Market:

  • Asia-Pacific is expected to register the highest growth rate from 2018 to 2025 in the neurological biomarkers market for Alzheimers.
  • The U.S. accounted for maximum revenue in 2017 in the market for both Alzheimers and Parkinsons, and is anticipated to maintain this trend throughout the forecast period.
  • EU5 region generated second highest revenue in 2017 in the market for both Alzheimers & Parkinsons, and is expected to continue this trend throughout the forecast period.
  • China is estimated to exhibit the highest CAGR of 10.1% from 2018 to 2025 in the neurological biomarkers market for Parkinsons disease.

The major companies profiled in this report include Abbott Laboratories, Myriad RBM, Proteome Sciences, Thermo Fisher Scientific, Athena Diagnostics, Immunarray Pvt. Ltd.,

Quanterix Corporation, Diagenic ASA, Psynova Neurotech, and Bio-Rad Laboratories. Other prominent players in the value chain include Qiagen, AbaStar MDx, Acumen Pharmaceuticals, Abiant, Alseres Pharmaceuticals, Athena Diagnostics, Banyan Biomarkers, and ProteoSys AG.

Need More Information

pr-det-talk Talk to David (Europe)

pr-det-talk Talk to Sona Padman (Americas)

5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States

pr-det-phone Toll Free: +1-800-792-5285

pr-det-phone UK: +44-845-528-1300

pr-det-phone Hong Kong: +852-301-84916

pr-det-phone India (Pune): +91 2066346060

pr-det-phone Fax: +1(855) 550-5975

pr-det-phone help@alliedmarketresearch.com

 

For Media Inquiries, Please Contact

Abhinav Rautela
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
mediacommunications@alliedanalytics.com

 
 

First time buyer?
Check offers and discount on this report
To get this report

 
Click Here
 
 

quote Neurological Biomarkers Market for Alzheimers and Parkinsons Diseases - Global Opportunity Analysis and Industry Forecast, 2018-2025 quote

View Report
 
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

Targeted Market View

Targeted market view to provide pertinent information and save time of readers

 

Featured Readings

 
 

Get Fresh content delivered

Get insights on topics that matter to your business. Stay updated on the area that interests you.

 
Get Industry Data Alerts
 

Buy Full Version
"Neurological Biomarkers Market"
Purchase Enquiry